Formulation and transport properties of tenofovir loaded liposomes through Caco-2 cell model

References

• Aramaki Y, Takano S, Arima H, Tsuchiya S. (2000). Induction of apoptosis in wehi 231 cells by cationic liposomes. Pharm Res 17:515–20
   PubMed Web of Science ®Google Scholar
• Artursson P. (1991). Cell cultures as models for drug absorption across the intestinal mucosa. Therap Drug Carrier Syst 8:305–30
   PubMed Web of Science ®Google Scholar
• Artursson P, Karlsson J. (1991). Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 175:880–5
   PubMed Web of Science ®Google Scholar
• Balda M, Whitney J, Flores C, et al. (1996). Functional dissociation of paracellular permeability and transepithelial electrical resistance and disruption of the apical-basolateral intramembrane diffusion barrier by expression of a mutant tight junction membrane protein. J Cell Biol 134:1031–49
   PubMed Web of Science ®Google Scholar
• Balimane PV, Han YH, Chong S. (2006). Current industrial practices of assessing permeability and p-glycoprotein interaction. AAPS J 8:E1–13
   PubMed Web of Science ®Google Scholar
• Banerjee A, Roychoudhury J, Ali N. (2008). Stearylamine-bearing cationic liposomes kill leishmania parasites through surface exposed negatively charged phosphatidylserine. J Antimicrob Chemother 61:103–10
   PubMed Web of Science ®Google Scholar
• Barditch-Crovo P, Deeks S, Collier A, et al. (2001). Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in HIV-1 infected adults. Antimicrob Agents Chemother 45:2733–9
   PubMed Web of Science ®Google Scholar
• Bathori G, Cervenak L, Karadi I. (2004). Caveolae – an alternative endocytotic pathway for targeted drug delivery. Crit Rev Ther Drug 21:67–95
   PubMed Web of Science ®Google Scholar
• Betageri GV. (2005). Proliposomal drug delivery system. US Patent 6,849,269
   Google Scholar
• Brocks DR, Betageri GV. (2002). Enhanced oral absorption of halofantrine enantiomers after liposomal encapsulation. J Pharm Pharmacol 54:1049–53
   PubMed Web of Science ®Google Scholar
• Chaudhari KB, Labhasetwar V, Dorle AK. (1994). Liposomes as a carrier for oral administration of insulin: effect of formulation factors. J Microencapsul 11:319–25
   PubMed Web of Science ®Google Scholar
• Cihlar T, Bischofberger N. (1998). PMEA and PMPA: acyclic nucleoside phosphonates with potent anti-HIV activity. In: Van der Goot H, ed. Trends in drug research II. Amsterdam: Elsevier, 105–16
   Google Scholar
• Clumeck N, De Wit S. (2000). Update on highly active antiretroviral therapy: progress and strategies. Biomed Pharmacother 54:7–12
   PubMed Web of Science ®Google Scholar
• Deleers M, Guilmin T, Vandenbranden M, Ruysschaert JM. (1982). Thermotropic properties of dipalmitoyl phosphatidyl choline stearylamine liposomes. Pharmacol Res Commun 14:333–42
   Google Scholar
• Deleers M, Malaisse WJ. (1980). Ionophore-mediated calcium exchange diffusion in liposomes. Biochem Biophys Res Commun 95:650–7
   PubMed Web of Science ®Google Scholar
• Deshmukh DD, Ravis WR, Betageri GV. (2008). Improved delivery of cromolyn from oral proliposomal beads. Int J Pharm 358:128–36
   PubMed Web of Science ®Google Scholar
• Desormeaux A, Bergeron MG. (1998). Liposomes as drug delivery system: a strategic approach for the treatment of HIV infection. J Drug Target 6:1–15
   PubMed Web of Science ®Google Scholar
• Embretson J, Zupancic M, Ribas JL, et al. (1993). Massive covert infection of helper T-lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 362:359–62
   PubMed Web of Science ®Google Scholar
• Fardis M, Oliyai R. (2007). Case study: tenofovir disoproxil fumarate: an oral prodrug of tenofovir. Biotechnol Pharm Aspects 5:1347–57
   Google Scholar
• Fendler JH. (1980). Optimizing drug entrapment in liposomes: chemical and biophysical considerations. In: Gregoriadis G, Allison AC, eds. Liposomes in biological systems. New York: John Wiley and Sons, 87
   Google Scholar
• Gilead Sciences, Inc. (2001). Viread (Tenofovir) Product Monograph. Submission Control No.: 151402. Foster City (CA): Gilead Sciences, Inc. Available from: http://www.gilead.ca/pdf/ca/viread_pm_english.pdf [last accessed 25 June 2013]
   Google Scholar
• Gregoriadis G, Davisson PJ, Scott S. (1977). Binding of drugs to liposome-entrapped macromolecules prevents diffusion of drugs from liposomes in vitro and in vivo. Biochem Soc Trans 5:1323–9
   PubMed Web of Science ®Google Scholar
• Harder T, Simons K. (1997). Caveolae, digs, and the dynamics of sphingolipid-cholesterol microdomains. Curr Opin Cell Biol 9:534–42
   PubMed Web of Science ®Google Scholar
• Hovgaard L, Brondsted H, Nielsen HM. (1995). Drug delivery studies in caco-2 monolayer. II. absorption enhancer effects of lysophosphatdylcholines. Int J Pharm 114:141–9
   Web of Science ®Google Scholar
• Huth US, Schubert R, Peschka-Süss R. (2006). Investigating the uptake and intracellular fate of ph-sensitive liposomes by flow cytometry and spectral bio-imaging. J Control Release 110:490–504
   PubMed Web of Science ®Google Scholar
• Jin SX, Bi DZ, Wang J, et al. (2005). Pharmacokinetics and tissue distribution of zidovudine in rats following intravenous administration of zidovudine myristate loaded liposomes. Pharmazie 60:840–3
   PubMed Web of Science ®Google Scholar
• Johansson F, Hjertberg E, Eirefelt S, et al. (2002). Mechanism for absorption enhancement of inhaled insulin by sodium taurocholate. Eur J Pharm Sci 17:63–71
   PubMed Web of Science ®Google Scholar
• Jullien V, Tréluyer J, Pons G, Rey E. (2003). Determination of tenofovir in human plasma by high-performance liquid chromatography with spectrofluorimetric detection. J Chromatogr B 785:377–81
   PubMed Web of Science ®Google Scholar
• Kapitza SB, Michel BR, Hoogevest P, et al. (2007). Absorption of poorly water soluble drugs subject to apical efflux using phospholipids as solubilizers in the Caco-2 cell model. Eur J Pharm Biopharm 66:146–58
   PubMed Web of Science ®Google Scholar
• Knight CG, ed. (1981). Interactions of phospholipid vesicles with mammalian cells in vitro: studies of mechanism. In: Liposomes: from physical structure to therapeutic applications. Amsterdam: Elsevier, 381
   Google Scholar
• Kulkarni SB, Betageri GV, Singh M. (1995). Factors affecting microencapsulation of drugs in liposomes. J Microencapsul 12:229–46
   PubMed Web of Science ®Google Scholar
• Lakeram M, Lockley D, Pendlington R, Forbes B. (2008). Optimization of the Caco-2 permeability assay using experimental design methodology. Pharm Res 25:1544–51
   PubMed Web of Science ®Google Scholar
• MacDonald WE, Deichmann WB, Radomski JL, Austin BS. (1962). The chronic toxicity of octadecylamine in the rat – a supplemental report. Toxicol Appl Pharmacol 4:610–2
   PubMed Web of Science ®Google Scholar
• O’leary G, Degim Z, Gumbleton M, Mcguigan C. (1996). Permeability of caco-2 novel d4t-monophosphate prodrugs. Eur J Pharm Sci 4:194–4(1)
   Google Scholar
• Ojewole E, Mackraj I, Naidoo P, Govender T. (2008). Exploring the use of novel drug delivery systems for antiretroviral drugs. Eur J Pharm Biopharm 70:697–710
   PubMed Web of Science ®Google Scholar
• Pantaleo G, Graziosi C, Demarest JF, et al. (1993). HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362:355–8
   PubMed Web of Science ®Google Scholar
• Parmentier J, Hartmann FJ, Fricker G. (2010). In vitro evaluation of liposomes containing bio-enhancers for the oral delivery of macromolecules. Eur J Pharm Biopharm 76:394–403
   PubMed Web of Science ®Google Scholar
• Payne NI, Timmis P, Ambrose CV, Warel MD. (1986). Proliposomes: a novel solution to an old problem. J Pharm Sci 75:325–9
   PubMed Web of Science ®Google Scholar
• Petrossian VD, Worthington JH, Strickley RG, Wu S. (2003). Development of a palatable oral suspension containing tenofovir disoproxil fumarate. AAPS annual meeting, Abstract number AAPS2003-002979
   Google Scholar
• Philips NC. (1992). Liposomal carriers for the treatment of acquired immune deficiency syndrome. Bull Inst Pasteur 90:205–30
   Google Scholar
• Pisal DS, Yellepeddi VK, Kumar A, et al. (2008). Permeability of surface-modified polyamidoamine (PAMAM) dendrimers across Caco-2 cell monolayers. Int J Pharm 350:113–21
   PubMed Web of Science ®Google Scholar
• Rajesh K, Gupta RB, Betageri GV. (2001). Formulation, characterization, and in vitro release of glyburide from proliposomal beads. Drug Deliv 8:25–7
   PubMed Web of Science ®Google Scholar
• Saarinen-Savolainen P, Jarvinen T, Taipale H, Urtti A. (1997). Method for evaluating drug release from liposomes in sink conditions. Int J Pharm 159:27–33
   Web of Science ®Google Scholar
• Schooley R, Myers R, Ruane P, et al. (2000). Tenofovir disoproxil fumarate (TDF) for the treatment of antiretroviral experienced patients. A double-blind placebo-controlled study. 40th International Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada
   Google Scholar
• Senior J. (1987). Fate and behaviour of liposomes in vivo: a review of controlling factors. Ther Drug Carrier Syst 3:123–93
   PubMed Web of Science ®Google Scholar
• Senior J, Gregoriadis G. (1984). Liposome technology. In: Gregoriadis G, ed. Targeted drug delivery and biological interaction. Vol. III. FL: CRC Press Inc, 263
   Google Scholar
• Sharma A. (1997). Liposomes in drug delivery: progress and limitations. Int J Pharm 154:123–40
   Web of Science ®Google Scholar
• Van Gelder J, Deferme S, Annaert P. (2000). Increased absorption of the antiviral ester prodrug tenofovir disoproxil in rat ileum by inhibiting its intestinal metabolism. Drug Metab Dispos 28:1394–400
   PubMed Web of Science ®Google Scholar
• Ward PD, Tippin TK, Thakker DR. (2000). Enhancing paracellular permeability by moduating epithelial tight junctions. Pharm Sci Technol Today 3:346–58
   PubMedGoogle Scholar